Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer; A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age

By Rose C.  

Breast Cancer Research and Treatment, Vol. 61, Iss. 2, 2000-05 ,pp. : 103-110

Springer Publishing Company

Access to resources Recommend Favorite

Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer

By Cella David   Fallowfield Lesley   Barker Peter   Cuzick Jack   Locker Gershon   Howell Anthony  

Breast Cancer Research and Treatment, Vol. 100, Iss. 3, 2006-12 ,pp. : 273-284

Springer Publishing Company

Access to resources Recommend Favorite

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3 years treatment with tamoxifen in Sweden

By Lundkvist Jonas   Wilking Nils   Holmberg Stig   Jönsson Linus  

Breast Cancer Research and Treatment, Vol. 102, Iss. 3, 2007-05 ,pp. : 289-299

Springer Publishing Company

Access to resources Recommend Favorite

Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis

By Peethambaram P.P.   Ingle J.N.   Suman V.J.   Hartmann L.C..   Loprinzi C.L.  

Breast Cancer Research and Treatment, Vol. 54, Iss. 2, 1999-03 ,pp. : 117-122

Springer Publishing Company

Access to resources Recommend Favorite

High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment

By Kvinnsland S.   Anker G.   Dirix L.-Y.   Bonneterre J.   Prove A.-M.   Wilking N.   Lobelle J.-P.   Mariani O.   di Salle E.   Polli A.   Massimini G.  

European Journal of Cancer, Vol. 36, Iss. 8, 2000-05 ,pp. : 976-982

Elsevier

Access to resources Recommend Favorite